DURECT Corporation (DRRX)

Market Cap	25.02M
Revenue (ttm)	2.03M
Net Income (ttm)	-7.87M
Shares Out	31.04M
EPS (ttm)	-0.25
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	59,654
Open	0.805
Previous Close	0.806
Day's Range	0.800 - 0.806
52-Week Range	0.700 - 1.880
Beta	0.91
Analysts	Buy
Price Target	5.00 (+520.35%)
Earnings Date	Mar 26, 2025

About DRRX

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company’s lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osm...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Sep 28, 2000
• Employees: 58
• Stock Exchange: NASDAQ
• Ticker Symbol: DRRX
• Website: https://www.durect.com

Financial Performance

In 2024, DURECT's revenue was $2.03 million, a decrease of -76.24% compared to the previous year's $8.55 million. Losses were -$7.87 million, -71.50% less than in 2023.

Analyst Forecast

According to 2 analysts, the average rating for DRRX stock is "Buy." The 12-month stock price forecast is $5.0, which is an increase of 520.35% from the latest price.

Price Target

$5.0

(520.35% upside)

Analyst Consensus: Buy